Logo for Poxel S.A.

Poxel Investor Relations Material

Latest events

Logo for Poxel S.A.

H1 2023

Poxel
Logo for Poxel

Q2 2024 TU

9 Sep, 2024
Logo for Poxel

Q2 2024 TU

15 Jul, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Poxel S.A.

Access all reports
Poxel S.A. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for serious chronic diseases, particularly those related to metabolic disorders. The company's research pipeline includes treatments for conditions like non-alcoholic steatohepatitis (NASH) and rare metabolic diseases such as adrenoleukodystrophy (ALD). Poxel leverages proprietary platforms including adenosine monophosphate-activated protein kinase (AMPK) activators and deuterated thiazolidinedione (TZD) compounds. The company is headquartered in Lyon, France, with additional offices in Boston, Massachusetts, and Tokyo, Japan. Its shares are listed on Euronext Paris.